The 2018 marketing guidelines for Medicare Advantage and Part D drug plans have now been released.
In it, CMS addressed the proposal of cutting out the FMO's when distributing MAPD and Part D drug plans, deciding to leave in the provision where they can make overrides (See 120.4.4).
Also addressed, individual agent websites do not have to be submitted to CMS for specific approval, so long as they are not misleading and they do not specify plans or benefits. They do still, however, have to be approved by the actual plan sponsors (MAPD or Part D companies). (See 100.7)
You can download the PDF here:CY-2018-Medicare-Marketing-Guidelines_Final072017
The text, in its entirety: